Vertex Pharmaceuticals Grants Program
The Vertex Pharmaceuticals Grants Program funds independent research and education to advance science in cystic fibrosis, sickle cell disease, diabetes, and related areas.
Browse similar grants
Funder: Vertex Pharmaceuticals
Due Dates: February 27, 2026 (Beta thalassemia & Sickle cell disease ISS RFP)
Funding Amounts: No fixed cap; requests must reflect fair market value. Typically, not more than 30% of an organization's annual operating budget per year. Multi-year and milestone-based funding possible.
Summary: Supports independent medical education, advocacy, and research initiatives in cystic fibrosis, sickle cell disease, diabetes, and related areas.
Key Information: Applications for most areas are rolling, but Beta thalassemia & Sickle cell disease ISS require submission by RFP deadline.
Description
Vertex Pharmaceuticals offers grants to advance independent medical education, patient advocacy, and research in disease areas aligned with its scientific priorities. The program is designed to enhance patient care, foster scientific innovation, and strengthen community engagement. Supported areas include cystic fibrosis, acute pain (U.S. only), APOL1-mediated kidney disease (U.S. only), beta thalassemia, IgA nephropathy, sickle cell disease, type 1 diabetes, and select rare diseases. Funding is available for both accredited and non-accredited educational projects, organizational initiatives, and investigator-initiated research.
